Cellebrite DI Ltd. research snapshot
CLBT AI stock analysis currently reads Cellebrite DI Ltd. as a digital intelligence and forensics software leader with strong government penetration, high switching costs from certified workflows and training, improving recurring revenue, and a clean balance sheet. At the August 3, 2026 cutoff, the real-time quote was $14.95 and market capitalization was about $3.73 billion. The stock trades between its 50-day and 200-day moving averages, with a 7-analyst consensus of Strong Buy and an average price target of $21.00. The main decision point is whether sustained high-teens revenue growth, margin expansion, and the Genesis and FedRAMP-driven federal opportunity justify the current valuation. This is informational research and not investment advice.
Current price
$14.95
Market cap
$3.73 billion
AI score
64 / 100
Rating
Niche leader, solid execution
Trend status
Neutral, consolidating between key moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Cellebrite sells digital forensics software and services to law enforcement, government, and enterprise customers for legally sanctioned investigations, with about 71% of TTM revenue from subscription services and an 84% gross margin. | High |
| Moat | Moat comes from certified workflows and training lock-in, multi-year government procurement relationships, FedRAMP High authorization, regulatory and chain-of-custody compliance barriers, and 25 years of brand trust in the forensic community. | High |
| Management | Management has execution credibility from 21% ARR growth and a 32% TTM free cash flow margin, but CEO Thomas Hogan selling about 103,000 shares in mid-2026 and the product leadership transition to Shiven Ramji are watch points. | Medium |
| Financial trend | Revenue grew about 18.4% over the trailing twelve months to $496.43 million, with net income of roughly $71 million, free cash flow of $158.62 million, and a net cash position of about $406 million. | Medium-high |
| Valuation | At about 52.7x trailing earnings, 25.6x forward earnings, and 7.5x sales, the stock prices in continued growth. The forward multiple is more balanced than the trailing multiple if growth holds. | Medium-low |
| Technical trend | Neutral. The stock traded at $14.95 on August 3, 2026, above its 50-day average ($14.29) but below its 200-day average ($15.28), with RSI near 50 and a 52-week price change of about +3.5%. | Medium |
| Risk level | The thesis can fail if government budgets tighten, privacy regulations limit digital forensics tools, competition from Palantir, MSAB, or open-source options emerges, or key customer concentration creates revenue risk. | Medium-high |
| AI confidence | Medium-high data confidence for qualitative mapping and quote math. Lower confidence for forward returns given the niche market dynamics and the August 13, 2026 earnings report. | Medium-high |
| Investment certainty | Medium certainty because the page gives a framework, not a personalized buy or sell instruction. The niche has defensibility, but valuation and insider signals limit forward certainty. | Medium |
CLBT AI stock forecast
The CLBT AI stock forecast uses scenario ranges around the $14.95 quote rather than a point target. The bullish case requires ARR growth to stay above 20% with federal expansion; the base case assumes steady high-teens growth at current multiples; the bearish case assumes budget, regulatory, or competitive headwinds compress the multiple.
$19.00 to $23.50
More likely if Cellebrite DI Ltd. sustains ARR growth above 20%, Genesis adoption and FedRAMP High authorization expand federal and international revenue, margins keep expanding, and the stock re-rates toward the $21 average analyst target and beyond.
$14.50 to $19.00
More likely if revenue keeps growing in the high teens, margins hold near current levels, and the stock trades toward the $15 to $21 analyst target band through the August 13, 2026 earnings report.
$10.50 to $14.50
More likely if these risk paths appear: government budget cuts reduce procurement, privacy regulation limits tool deployment, competition from Palantir, MSAB, or open-source alternatives erodes the position, or a weak Q2 print sends the price below the 50-day average toward the 52-week low near $11.02.
CLBT AI technical analysis
CLBT AI technical analysis starts from the $14.95 real-time quote on August 3, 2026. Because this static page does not fetch request-time chart data, confirm moving averages and momentum in a charting tool before use. At the cutoff the stock sat above its 50-day average and below its 200-day average.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $14.95 | Real-time quote as of August 3, 2026 (intraday), up about 1.4% from the $14.75 previous close. |
| Near support | $14.20 to $14.80 | The zone around the 50-day moving average ($14.29) and recent day-range lows. Treat as a planning zone, not a guaranteed floor. |
| Near resistance | $15.28 to $16.10 | The 200-day moving average ($15.28) followed by recent highs. A clean break above this zone with volume would signal renewed momentum. |
| 52-week high | $19.98 | The upper boundary of the price range from the past year. A move above this level would require a significant catalyst. |
| 52-week low | $11.02 | Lower boundary of the trailing 52-week range, well below the current price. |
| 50-day moving average | $14.29 | Live chart data as of August 3, 2026. The stock traded just above this average at the cutoff. |
| 200-day moving average | $15.28 | Live chart data as of August 3, 2026. The stock traded just below this long-term trend reference. |
| Momentum | Neutral, RSI near 49.8 | The stock sits between its 50-day and 200-day averages with a neutral relative strength reading. A breakout needs fresh catalyst confirmation. |
| Volume | About 1.33M shares on the 20-day average | Short interest was about 7.01 million shares, near 5.7% of float, which can add volatility around news and earnings. |
| Volatility | Moderate monitoring priority | The stock has a beta of 1.17. Use position sizing that can tolerate moderate daily movement. |
| Invalidation | Close below $14.20 | A decisive close below the support zone would weaken the short-term setup and point toward the lower part of the 52-week range. |
CLBT AI trading strategy
The CLBT AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with position sizing, stop levels, and fresh filings or news checks around the August 13, 2026 earnings report.
Wait for CLBT to hold above the $14.20-$14.80 support zone and push through the $15.28-$16.10 resistance band with volume that confirms renewed buyer demand, ideally after a strong Q2 report or a federal contract win.
A close below $14.20 or a failed breakout should invalidate the setup.
If CLBT dips toward the $14.20-$14.80 support band without a thesis-changing event, evaluate the government budget outlook, competitors, and recent insider activity before considering a position.
Do not average down without a predefined maximum loss and a fresh review of the business risk.
Track the evidence that matters most for digital forensics: ARR growth rate, gross margin, subscription share of revenue, free cash flow margin, Genesis and FedRAMP-driven federal wins, and regulatory developments.
Reduce confidence when price moves are driven by headlines without matching financial evidence or when insider selling accelerates.
Investment research summary
Cellebrite sells digital forensics software and services that let law enforcement, government agencies, and enterprises extract, analyze, and manage digital evidence from mobile devices and cloud sources for legally sanctioned investigations. Subscription services made up about 71% of trailing twelve month revenue.
Cellebrite's moat comes from certified workflow lock-in through investigator training programs, deep government procurement relationships that take years to displace, FedRAMP High authorization, regulatory and chain-of-custody compliance requirements, and brand trust built over 25 years in the digital forensics community.
The thesis can fail if government budgets tighten and delay procurement cycles, privacy regulation limits digital forensics tool deployment, a well-funded competitor such as Palantir, Axon, or MSAB enters the niche more aggressively, or decryption and mobile security advances make current extraction methods less effective.
Management has shown execution capability with 21% ARR growth, a 32% TTM free cash flow margin, and a net cash balance sheet. The mid-2026 sale of about 103,000 shares by the CEO and the product leadership transition to former Okta executive Shiven Ramji are watch points that need monitoring for pattern rather than single signals.
Digital evidence volumes are growing as mobile device usage and cloud storage expand, and law enforcement agencies globally are investing in digital investigation capabilities. Genesis, the new AI investigation platform, and FedRAMP High authorization position Cellebrite for federal expansion within this long-term secular trend.
At about 52.7x trailing earnings and 7.5x sales, the stock embeds an expectation of continued growth. The forward multiple of about 25.6x is more balanced if growth holds. Net cash of roughly $406 million supports the balance sheet, but margin of safety depends on whether growth re-accelerates or the multiple compresses.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CLBT price | $14.95, up about 1.4% intraday | StockAnalysis.com real-time quote (CBOE and Nasdaq UTP pricing) | August 3, 2026 |
| Market capitalization | $3.73 billion, consistent with $14.95 x about 249.44 million shares | StockAnalysis.com market cap data | August 3, 2026 |
| Exchange | NasdaqGS | StockAnalysis.com and Nasdaq quote pages | August 3, 2026 |
| Revenue (TTM) | $496.43 million, up about 18.4% | StockAnalysis.com financials (Fiscal.ai data) | August 3, 2026 |
| Net income (TTM) | About $71 million; FY2025 net income $78.33 million | StockAnalysis.com financials and statistics | August 3, 2026 |
| Gross margin (TTM) | 83.86% | StockAnalysis.com financials | August 3, 2026 |
| Free cash flow (TTM) | $158.62 million, FCF margin about 32% | StockAnalysis.com statistics | August 3, 2026 |
| Cash and short-term investments | $429.07 million; total debt about $22.81 million | StockAnalysis.com financials | August 3, 2026 |
| P/E ratio (TTM) | 52.73; forward P/E 25.56 | StockAnalysis.com statistics | August 3, 2026 |
| Analyst consensus | Strong Buy from 7 analysts, average price target $21.00, range $15 to $28 | StockAnalysis.com forecast (S&P Global and TipRanks analyst data) | August 3, 2026 |
| 52-week range | $11.02 to $19.98 | StockAnalysis.com quote | August 3, 2026 |
| Moving averages and RSI | 50-day average $14.29, 200-day average $15.28, RSI near 49.76 | StockAnalysis.com statistics | August 3, 2026 |
| Earnings date | August 13, 2026, before market open | StockAnalysis.com quote and Cellebrite press release | July 21, 2026 |
| Financial statement depth | Public filings available. Two-source statement checks still recommended before investment use. | Research quality check | August 3, 2026 |
This CLBT AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 3 to 4, 2026, may be incomplete, and can be wrong if new filings, market prices, company events, or macro conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
